Transferrin iron starvation therapy for lethal bacterial and fungal infections

Journal of Infectious Diseases

Volumn 210, Issue 2, 2014, Pages 254-264

  Lin, Lin ^a,b,c   Pantapalangkoor, Paul ^a   Tan, Brandon ^a   Bruhn, Kevin W ^a,b,c   Ho, Tiffany ^a   Nielsen, Travis ^a   Skaar, Eric P ^d   Zhang, Yaofang ^d   Bai, Ruipeng ^a   Wang, Amy ^a   Doherty, Terence M ^a   Spellberg, Brad ^a,b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida albicans

Indexed keywords

DEFEROXAMINE; ENTEROCHELIN; FERRIC CHLORIDE; IRON; PLACEBO; PROTEIN ANTIBODY; RIFAMPICIN; TRANSFERRIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM MUTANT; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TARGETING; EMBRYO; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; HOST; LETHALITY; MALE; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEM CELL CONDITIONED MEDIUM; SURVIVAL;

ACINETOBACTER BAUMANNII; CANDIDA ALBICANS; IN VIVO TREATMENT; IRON; STAPHYLOCOCCUS AUREUS; TRANSFERRIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; CELLS, CULTURED; HUMANS; IRON; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 84903979257     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu049     Document Type: Article

References (54)

1. Spellberg B, Blaser M, Guidos R, et al. for the Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52(S5):S397-428.
2. Choffnes ER, Relman DA, Mack A. for the Forum on Microbial Threats, Institute of Medicine of the National Academies. Antibiotic resistance: implications for global health and novel intervention strategies. Washington, DC. The National Academies Press, 2010.
3. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013; 368:299-302.
4. Goel VK, Kapil A. Monoclonal antibodies against the iron regulated outer membrane proteins of Acinetobacter baumannii are bactericidal. BMC Microbiol 2001; 1:16.
5. Actis LA, Tolmasky ME, Crosa LM, Crosa JH. Effect of iron-limiting conditions on growth of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 1993; 31:2812-5. (Pubitemid 23284933)
6. Aguila A, Herrera AG, Morrison D, et al. Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immunol Med Microbiol 2001; 31:145-52. (Pubitemid 32822879)
7. Goel VK, Kapil A, Das B, Rao DN. Influence of iron on growth and extracellular products of Acinetobacter baumannii. Jpn J Med Sci Biol 1998; 51:25-33.
8. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74:2215-23.
9. Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O. Iron-source preference of Staphylococcus aureus infections. Science 2004; 305: 1626-8. (Pubitemid 39296358)
10. Skaar EP, Schneewind O. Iron-regulated surface determinants (Isd) of Staphylococcus aureus: stealing iron from heme. Microbes Infect 2004; 6:390-7. (Pubitemid 38393820)
11. Sutak R, Lesuisse E, Tachezy J, Richardson DR. Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol 2008; 16:261-8.
12. Skaar EP. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 2010; 6:e1000949.
13. Crusio R, Rao S, Changawala N, et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis 2013; 46:1-8.
14. Bezkorovainy A, Topouzian N. The effect of metal chelators and other metabolic inhibitors on the growth of Bifidobacterium bifidus var. Pennsylvanicus. Clin Biochem 1981; 14:135-41. (Pubitemid 12176603)
15. Dorsey CW, Tomaras AP, Connerly PL, Tolmasky ME, Crosa JH, Actis LA. The siderophore-mediated iron acquisition systems of Acinetobacter baumannii ATCC 19606 and Vibrio anguillarum 775 are structurally and functionally related. Microbiology 2004; 150(Pt 11):3657-67. (Pubitemid 39545313)
16. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117:2649-57. (Pubitemid 47494365)
17. Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007; 71:413-51. (Pubitemid 47429279)
18. von Bonsdorff L, Sahlstedt L, Ebeling F, Ruutu T, Parkkinen J. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 2003; 37:45-51. (Pubitemid 36588927)
19. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-82.
20. Forsberg CM, Bullen JJ. The effect of passage and iron on the virulence of Pseudomonas aeruginosa. J Clin Pathol 1972; 25:65-8.
21. Bezkorovainy A. Antimicrobial properties of iron-binding proteins. Adv Exp Med Biol 1981; 135:139-54.
22. Ellison RT III, LaForce FM, Giehl TJ, Boose DS, Dunn BE. Lactoferrin and transferrin damage of the gram-negative outer membrane is modulated by Ca2+ and Mg2+. J Gen Microbiol 1990; 136:1437-46. (Pubitemid 20238484)
23. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006; 55(Pt 3):251-8.
24. Rooijakkers SH, Rasmussen SL, McGillivray SM, et al. Human transferrin confers serum resistance against Bacillus anthracis. J Biol Chem 2010; 285:27609-13.
25. Brandsma ME, Jevnikar AM, Ma S. Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv 2011; 29:230-8.
26. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67:715-22.
27. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
28. Luo G, Lin L, Ibrahim AS, et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One 2012; 7:e29446.
29. Barry AL, Craig WA, Nadler H, Reller LB, Sanders CC, Swenson JM. Methods for determining bactericidal activity of antimicrobial agents. M26-A. Vol. 19: Clinical and Laboratory Standards Institute (formerly NCCLS), 1999.
30. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004; 38:864-70. (Pubitemid 38387236)
31. Hood MI, Mortensen BL, Moore JL, et al. Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog 2012; 8: e1003068.
32. Bird LJ, Bonnefoy V, Newman DK. Bioenergetic challenges of microbial iron metabolisms. Trends Microbiol 2011; 19:330-40.
33. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264:388-93. (Pubitemid 24986723)
34. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat Rev Microbiol 2004; 2:946-53. (Pubitemid 39562533)
35. Hershko C. Oral iron chelating drugs: coming but not yet ready for clinical use. Br Med J (Clin Res Ed) 1988; 296:1081-2. (Pubitemid 18097364)
36. Gordeuk VR, Thuma PE, Brittenham GM, et al. Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 1993; 48:193-7. (Pubitemid 23083734)
37. Santos AL, Sodre CL, Valle RS, et al. Antimicrobial action of chelating agents: repercussions on the microorganism development, virulence and pathogenesis. Curr Med Chem 2012; 19:2715-37.
38. Wandersman C, Delepelaire P. Bacterial iron sources: from siderophores to hemophores. Ann Rev Microbiol 2004; 58:611-47. (Pubitemid 39551999)
39. Fischbach MA, Lin H, Liu DR, Walsh CT. How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nat Chem Biol 2006; 2:132-8. (Pubitemid 44323863)
40. Baker HM, Baker EN. Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals 2004; 17:209-16. (Pubitemid 38987139)
41. Funahashi T, Tanabe T, Mihara K, Miyamoto K, Tsujibo H, Yamamoto S. Identification and Characterization of an Outer Membrane Receptor Gene in Acinetobacter baumannii required for utilization of desferricoprogen, rhodotorulic acid, and desferrioxamine B as xenosiderophores. Biol Pharm Bull 2012; 35:753-60.
42. Heymann P, Gerads M, Schaller M, Dromer F,Winkelmann G, Ernst JF. The siderophore iron transporter of Candida albicans (Sit1p/Arn1p) mediates uptake of ferrichrome-type siderophores and is required for epithelial invasion. Infect Immun 2002; 70:5246-55.
43. Haas H. Molecular genetics of fungal siderophore biosynthesis and uptake: the role of siderophores in iron uptake and storage. Appl Microbiol Biotechnol 2003; 62:316-30. (Pubitemid 37214912)
44. Bernier G, Girijavallabhan V, Murray A, et al. Desketoneoenactinsiderophore conjugates for Candida: evidence of iron transport-dependent species selectivity. Antimicrob Agents Chemother 2005; 49:241-8. (Pubitemid 40065798)
45. Lee JH, Han Y. Candida albicans can utilize siderophore during candidastasis caused by apotransferrin. Arch Pharm Res 2006; 29:249-55. (Pubitemid 43699538)
46. Sande MA, Mandell GL. Effect of rifampin on nasal carriage of Staphylococcus aureus. Antimicrob Agents Chemother 1975; 7: 294-7.
47. Sande MA. The use of rifampin in the treatment of nontuberculous infections: an overview. Rev Infect Dis 1983; 5(Suppl 3):S399-401.
48. Simon GL, Smith RH, Sande MA. Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases. Rev Infect Dis 1983; 5 (Suppl 3):S507-8.
49. Zavasky DM, Sande MA. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 1998; 279:1575-7. (Pubitemid 28233016)
50. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455-62.
51. Cappellini MD, Giardina P, Porter J, et al. Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade, ICL670) in patients with transfusional iron overload. Abstract 896. In: American Society of Hematology. Orlando, FL, 2006.
52. Piga A, Bejaoui M, Kilinc Y, et al. Long-term treatment with the oncedaily oral iron chelator deferasirox (Exjade, ICL1670) is effective and generally well tolerated in pediatric patients. Abstract 909. In: American Society of Hematology. Orlando, FL, 2006.
53. Gambino R, Desvarieux E, Orth M, et al. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem 1997; 43:2408-12. (Pubitemid 28022980)
54. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338:768-72.